Collectively, these results support the key oncogenic role of NEK2 and suggest that NEK2 targeting approaches represent promising therapeutic tools for TNBC treatment, whose efficacy could be amplified by co-targeting the vulnerability induced by splicing dysregulation in cancer cells. The gene discussed is NEK2; the disease is cancer.